Trial Profile
Evaluation of Bone Quality in Patients With Rheumatoid Arthritis Treated With Baricitinib: Single Centre, Mode of Action Study (BARE BONE)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Jan 2023
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms BAREBONE
- 14 Nov 2022 Results assessing the changes in bone strength in patients with active rheumatoid arthritis under baricitinib treatment using µFEA on the radial bone, presented at the ACR Convergence 2022.
- 04 Jun 2022 Results presented at the 23rd Annual Congress of the European League Against Rheumatism
- 14 Jan 2021 Planned End Date changed from 11 Sep 2020 to 11 Oct 2021.